to study which factors determine the balance between the antagonistic and agonistic effects of the angiotensin ii analogue [ sar1 , ala8 ] -angiotensin ii ( saralasin ) in man , saralasin was infused in subjects on a 'normal ' sodium intake ( group 1 ) during sodium restriction with appropriately elevated plasma angiotensin ii levels ( group 2 ) and in sodium-restricted subjects in whom plasma angiotensin ii was suppressed by converting enzyme inhibition with captopril ( group 3 ) .
C0036193
saralasin
C0003009
angiotensin ii